BioSpace News Archive

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the underwriter of its previously announced bought deal offering of common stock has partially exercised its option to purchase an additional 7,030,927 shares of common stock at a price to the public of $1.60 per share.

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it will report its financial results for the six and three months ended December 31, 2020 on Tuesday, March 2, 2021.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced that it will host a conference call to discuss its fourth quarter 2020 financial results on Monday, March 8th, 2021 at 7:30 a.m. Pacific Time.

- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94 ; Q3 Non-GAAP Diluted EPS of $1.29

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, provided business and portfolio updates and reported fourth quarter and full year 2020 financial results.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences: Cowen 41 st Annual Virtual Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET; and Oppenheimer 31 st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 9:20 a.m. ET.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming virtual investor conferences in March: Cowen 41 st Annual Health Care Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will participate in two upcoming investor conferences in March 2021: Cowen 41st Annual Health Care Conference Blazing New Paths in Clinical Development and Structure Panel Tuesday, March 2, 2021 at 2:10 pm ET

Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches that utilize autologous regulatory T cells (Tregs) and allogeneic exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB). Coya’s SAB is comprised of five world-renowned experts in regulatory T cell biology, cellular therapy, and neurodegeneration

Reductions in Debt Principal and Interest Rate Further Strengthen Balance Sheet, Support Ongoing Efforts to Best Position Company for Significant CDMO Business Growth